-
公开(公告)号：KR1020120139430A
公开(公告)日：2012-12-27
申请号：KR1020110059227
申请日：2011-06-17
Applicant: (주)아모레퍼시픽
IPC: C12N15/113 , A61K31/7088 , A61Q19/00 , A61Q7/00
Abstract: PURPOSE: A composition containing miRNA for controlling pigmentation gene expression is provided to suppress tyrosinase, tyrosinase-related proteins, and melan-A expression. CONSTITUTION: A composition for controlling pigmentation gene expression contains miRNA containing a base of sequence number 1 as an active ingredient. The miRNA has continuous 27 bases containing ccuucuu of sequence number 1 and a base which suppresses pigmentation gene expression. The pigmentation gene is tyrosinase, tyrosinase-related protein 1, or melan-A gene. The miRNA targets 909-915th nucleic acids of melan A mRNA 3'-UTR. The composition is a cosmetic or pharmaceutical composition for skin whitening. A composition for controlling pigmentation gene expression contains a complementary base with miRNA of sequence number 1. [Reference numerals] (AA) Relative TYR/GAPDH mRNA expression level; (BB) Comparative embodiment 1; (CC) Comparative embodiment 2; (DD) Embodiment 1
Abstract translation: 目的：提供含有miRNA用于控制色素沉着基因表达的组合物，以抑制酪氨酸酶，酪氨酸酶相关蛋白和黑色素A表达。 构成：用于控制色素沉着基因表达的组合物含有含有序列号1的碱基作为活性成分的miRNA。 miRNA具有连续的27个碱基，其含有序列号1的碱基和抑制色素沉着基因表达的碱基。 色素沉着基因是酪氨酸酶，酪氨酸酶相关蛋白1或黑色素A基因。 miRNA靶向黑色A mRNA 3'-UTR的第909-915个核酸。 该组合物是用于皮肤美白的化妆品或药物组合物。 用于控制色素沉着基因表达的组合物含有与序列号1的miRNA的互补碱基。[参考数字]（AA）相对TYR / GAPDH mRNA表达水平; （BB）比较实施例1; （CC）比较实施例2; （DD）实施例1
-
公开(公告)号：KR1020120128774A
公开(公告)日：2012-11-28
申请号：KR1020110046619
申请日：2011-05-18
Applicant: (주)아모레퍼시픽
CPC classification number: C12N5/0629 , C12N2500/14 , C12N2509/10
Abstract: PURPOSE: A method for sorting a cultured epithelial cell layer is provided to control calcium concentration by calcium pulse and to maximize skin regeneration. CONSTITUTION: A method for sorting a cultured epithelial cell layer comprises: a step of culturing keratinocytes in a basal medium; a step of changing the medium into a calcium medium of high content; a step of changing the medium into a basal medium; a step of removing basal medium and washing with a buffer solution; a step of exposing the washed keratinocytes to the air; and a step of adding a fresh buffer solution. The calcium medium contains 1.2-1.4 mM of CaCl_2. [Reference numerals] (AA) Basal medium 6 days(comparative embodiment 1); (BB) Basal medium 10 days(comparative embodiment 2); (CC) MRNA relative value
Abstract translation: 目的：提供一种用于分选培养的上皮细胞层的方法，以通过钙脉冲控制钙浓度并使皮肤再生最大化。 构成：用于分选培养的上皮细胞层的方法包括：在基础培养基中培养角质形成细胞的步骤; 将培养基更换成高含量的钙培养基的步骤; 将培养基更换为基础培养基的步骤; 除去基础培养基并用缓冲溶液洗涤的步骤; 将洗涤的角质形成细胞暴露于空气的步骤; 以及添加新鲜缓冲溶液的步骤。 钙介质含有1.2-1.4mM CaCl 2。 （AA）基础培养基6天（比较例1）; （BB）基础培养基10天（比较例2）; （CC）MRNA相对值
-
公开(公告)号：KR1020120098142A
公开(公告)日：2012-09-05
申请号：KR1020110017894
申请日：2011-02-28
Applicant: (주)아모레퍼시픽 , 서울대학교산학협력단
CPC classification number: G01K11/00 , A61B5/01 , A61B5/441 , A61Q17/04 , G01K13/002
Abstract: PURPOSE: A method for generating a heat protection factor is provided to generate a heat protection factor, thereby objectively evaluating an effect of a cosmetic product including heat protection materials. CONSTITUTION: A first area spread with heat protection materials and a second area which is no the heat protection materials are heated respectively(S1). Saturation temperature of the first area is measured(S3). The saturation temperature of the second area is measured. An energy corresponding to heat heated in the first area is divided into the saturation temperature of the first area for calculating a first energy(S5). The energy corresponding to heat heated in the second area is divided into the saturation temperature of the second area for calculating a second energy. A heat protection factor of the heat protection materials is calculated by dividing the first energy into the second energy(S6). [Reference numerals] (AA) Start; (BB) End; (S1) Applying heat in a first area where a heat protection material is spread and a second area where no heat protection material is spread; (S2) Periodically measuring the temperature of the first area and the second area; (S3) Determining whether the temperature of the first area and the second area reaches a saturation temperature; (S4) Calculating the minimum heating amount of the first area and the second area; (S5) Calculating first and second energy by using the minimum heating amount of the first area and the second area and the saturation temperature; (S6) Calculating a heat protection factor of a heat protection material by using the first and second energy
Abstract translation: 目的：提供一种产生热保护因子的方法以产生热保护因子，从而客观地评估包括耐热材料的化妆品的效果。 构成：分散加热保护材料的第一个区域和不是热保护材料的第二个区域（S1）。 测量第一区域的饱和温度（S3）。 测量第二区域的饱和温度。 对应于在第一区域中加热的热量的能量被划分为用于计算第一能量的第一区域的饱和温度（S5）。 对应于在第二区域中加热的热量的能量被分成用于计算第二能量的第二区域的饱和温度。 通过将第一能量除以第二能量来计算热保护材料的热保护系数（S6）。 （附图标记）（AA）开始; （BB）结束; （S1）在散热保护材料的第一区域和没有热保护材料扩散的第二区域施加热量; （S2）周期性地测量第一区域和第二区域的温度; （S3）确定第一区域和第二区域的温度是否达到饱和温度; （S4）计算第一区域和第二区域的最小加热量; （S5）通过使用第一区域和第二区域的最小加热量和饱和温度来计算第一和第二能量; （S6）通过使用第一和第二能量来计算热保护材料的热保护系数
-
公开(公告)号：KR1020120058687A
公开(公告)日：2012-06-08
申请号：KR1020100116410
申请日：2010-11-22
Applicant: (주)아모레퍼시픽
IPC: A61K8/37 , A61K8/368 , A61K8/36 , A61K8/49 , A61K8/89 , A61Q17/04 , A61K31/41 , A61K31/192 , A61K31/215 , A61K31/60
CPC classification number: A61K8/37 , A61K8/36 , A61K8/368 , A61K8/4966 , A61K8/89 , A61K31/192 , A61K31/215 , A61K31/41 , A61K31/60 , A61Q17/04
Abstract: PURPOSE: A composition containing cinnamic acid derivatives, triazine derivatives, and methoxy phenyl acrylate derivatives is provided to remarkably reduce chemical decomposition in case of irradiating with light. CONSTITUTION: A composition for sun screening contains cinnamic acid derivatives, triazine derivatives, and methoxy phenyl acrylate derivatives as an active ingredient. The triazine derivative includes bis-ethyl hexcyloxyphenyl methoxy phenyl triazine, tris(diisobutyl-aminobenzalmalonate)triazine, or combination thereof. The methoxyphenyl acrylate derivative is ethyl hexyl methoxy crylene. The composition further contains salicylic acid derivatives and benzalonate derivatives.
Abstract translation: 目的：提供含有肉桂酸衍生物，三嗪衍生物和甲氧基苯基丙烯酸酯衍生物的组合物，以显着减少在照射光时的化学分解。 构成：防晒组合物含有肉桂酸衍生物，三嗪衍生物和甲氧基苯基丙烯酸酯衍生物作为活性成分。 三嗪衍生物包括二乙基己氧基苯基甲氧基苯基三嗪，三（二异丁基 - 氨基苯甲醛丙二酸）三嗪或其组合。 甲氧基苯基丙烯酸酯衍生物是乙基己基甲氧基二烯丙基。 该组合物还含有水杨酸衍生物和苯甲酸酯衍生物。
-
公开(公告)号：KR1020120002482A
公开(公告)日：2012-01-05
申请号：KR1020110064247
申请日：2011-06-30
Applicant: (주)아모레퍼시픽
IPC: A61K38/16 , A61K31/7105 , A61P17/00
CPC classification number: A61K31/7105 , A61K8/64 , A61K31/7115 , A61K38/005 , A61K48/005 , A61Q19/08
Abstract: PURPOSE: A composition containing an oligonucleotide or mimic acting as an inhibitor of miRNA-526b is provided to control collagen generation and to prevent or treat aging. CONSTITUTION: A composition for controlling collagen contains 15-23 serial nucleotides of sequence number 1. The collagen is controlled by regulating the expression of matrix metalloproteinase 1(MMP1). The oligonucleotide reduces or suppresses the expression of MMP1 by hybridization with MMP1 mRNA. The composition is used for anti-aging.
Abstract translation: 目的：提供含有作为miRNA-526b抑制剂的寡核苷酸或模拟物的组合物，以控制胶原蛋白的产生和预防或治疗老化。 构成：用于控制胶原的组合物含有序列1的15-23个连续核苷酸。通过调节基质金属蛋白酶1（MMP1）的表达来控制胶原蛋白。 寡核苷酸通过与MMP1 mRNA杂交降低或抑制MMP1的表达。 该组合物用于抗衰老。
-
Patent Agency Ranking
公开(公告)号：KR1020110042837A
公开(公告)日：2011-04-27
申请号：KR1020090099686
申请日：2009-10-20
Applicant: (주)아모레퍼시픽
CPC classification number: A61K8/345 , A61K2800/30 , A61K2800/72 , A61Q19/00
Abstract: PURPOSE: An external use skin composition containing 1,8-octandiol is provided to ensure excellent usage, safety, and preservation and to be applied to cosmetic field. CONSTITUTION: An external use skin composition of low irritation contains 1,8-octandiol without separate preservative ingredients. A cosmetic composition contains the external use skin composition. The cosmetic composition is manufactured in the form of lotion, astringent, eye cream, nutrition cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence, or pack.
Abstract translation: 目的：提供含有1,8-辛二醇的外用皮肤组合物，以确保优异的使用，安全性和保存性，并适用于化妆品领域。 构成：低刺激的外用皮肤组合物含有1,8-辛二醇，没有单独的防腐成分。 化妆品组合物含有外用皮肤组合物。 化妆品组合物以洗剂，收敛剂，眼霜，营养霜，按摩膏，清洁霜，清洁泡沫，清洁水，粉末，精华或包装的形式制成。
-
公开(公告)号：KR101007088B1
公开(公告)日：2011-01-10
申请号：KR1020050135945
申请日：2005-12-30
Applicant: (주)아모레퍼시픽
IPC: A61K36/736 , A61P3/04
Abstract: 본 발명에 의한 지방산 산화 촉진용 조성물은 도인 추출물, 백개자 추출물, 백부근 추출물, 전호 추출물, 천오 추출물, 파두 추출물, 패장근 추출물 및 때죽나무 추출물로 구성된 군 중에서 선택된 하나 이상을 유효성분으로 함유함으로써, 인간 간세포주에서 지방산 산화조절에 중요한 역할을 하는 유전자인 CPT1A(Carnitine Palmitoyl Transferase 1A) 프로모터의 활성을 증가시켜 간에서 CPT1A 유전자 발현을 증가시키고 이를 통해 간에서 지방산의 산화를 촉진시키는 기능을 하며, 더 나아가 비만의 예방 또는 치료, 고지혈증의 예방 또는 치료에 이용될 수 있다.
도인, 백개자, 백부근, 전호, 천오, 파두, 패장근, 때죽나무, 지방산, 산화, CPT1A, 비만, 고지혈증-
228.发明授权ＣＰＴ-１ 유전자의 발현을 특이적으로 전사 단계에서조절하는 화학물질의 스크리닝 방법 및 그 방법으로검색된 제니스테인을 유효 성분으로 포함하는 ＣＰＴ-１발현 촉진제 有权用于表达CPT-1基因的控制剂的筛选方法，以及通过该方法筛选的包含染料木素的CPT-1表达增强子
公开(公告)号：KR100994632B1
公开(公告)日：2010-11-15
申请号：KR1020030095226
申请日：2003-12-23
Applicant: (주)아모레퍼시픽
IPC: C12N15/85
Abstract: 본 발명은, CPT-1 프로모터와 루시퍼라제를 포함하는 재조합 플라스미드; 상기 플라스미드로 형질전환된 Huh7 세포주 (수탁번호: KCLRF-BP-00090); 상기 세포를 이용하는 것을 특징으로 하는, CPT-1 유전자의 발현을 특이적으로 전사 단계에서 조절하는 화학물질의 스크리닝 방법에 관한 것이며,
또한 본 발명은, 상기의 스크리닝 방법으로 검색된 제니스테인을 유효 성분으로 포함하는 CPT-1 발현 촉진제; 그리고 상기의 스크리닝 방법으로 검색된 제니스테인을 유효 성분으로 포함하는 지방산의 베타 산화 촉진제에 관한 것이다.
제니스테인, CPT-1 유전자, 지방산의 베타 산화촉진제.-
229.发明公开
公开(公告)号：KR1020100103671A
公开(公告)日：2010-09-27
申请号：KR1020107017557
申请日：2008-12-03
Applicant: (주)아모레퍼시픽
CPC classification number: A61K31/15
Abstract: PURPOSE: A pharmaceutical composition containing 2-cyclopentene-1-one oxime derivative is provided to promote adipose lysis in adipocytes(3T3-L1) and to prevent and treat lipid metabolic diseases including obesity and diabetes. CONSTITUTION: A pharmaceutical composition for preventing and treating lipid metabolic diseases contains 2-cyclopenten-1-one oxime derivative compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, R1 is linear or branched C1-C10 alkyl group or C3-C7 cycloalkyl group, or phenyl group with or without substituent. The phenyl group is denoted by chemical formula 2. The pharmaceutical composition is used for preventing and treating obesity, diabetes, or dyslipidemia.
Abstract translation: 目的：提供含有2-环戊烯-1-酮肟衍生物的药物组合物，以促进脂肪细胞（3T3-L1）中的脂肪裂解，并预防和治疗脂肪代谢疾病，包括肥胖和糖尿病。 构成：用于预防和治疗脂质代谢疾病的药物组合物含有化学式1的2-环戊烯-1-酮肟衍生物化合物或其药学上可接受的盐作为活性成分。 在化学式1中，R 1为直链或支链C 1 -C 10烷基或C 3 -C 7环烷基，或具有或不具有取代基的苯基。 苯基由化学式2表示。药物组合物用于预防和治疗肥胖症，糖尿病或血脂异常。
-
公开(公告)号：KR1020100046668A
公开(公告)日：2010-05-07
申请号：KR1020080105619
申请日：2008-10-28
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: An evaluation method is provided to objectively measure the relief effect of sensory skin irritation by quantifying the relief effect of sensory skin irritation about various anti-irritants through the change of concrete threshold. CONSTITUTION: A sensory skin irritation relief effect evaluation method comprises a step of measuring the change of a threshold before and after spreading an anti-irritant to a stimulus applied to the skin sensory nerve. The evaluation method quantitatively measures the change of the threshold by using a device. The evaluation method measures the change of the threshold value about a stimulus applied to at least one skin sensory nerve which is selected in a group which includes Aα, Aβ, Aδ, and C-fiber type. The evaluation method measures the change of the threshold value about a stimulus which is applied to the skin sensory nerve of Aδ or C-fiber type.
Abstract translation: 目的：通过改变混凝土阈值，量化消除各种抗刺激剂对皮肤刺激的缓解作用，提供评估方法，客观地测量感觉皮肤刺激的缓解作用。 构成：感官皮肤刺激缓解效果评估方法包括测量在将抗刺激剂涂抹于皮肤感觉神经的刺激之前和之后的阈值变化的步骤。 评价方法通过使用装置定量地测量阈值的变化。 评估方法测量关于施加到包括Aα，Aβ，Aδ和C纤维类型的组中选择的至少一种皮肤感觉神经的刺激的阈值变化。 评估方法测量施加于Aδ或C纤维类型的皮肤感觉神经的刺激的阈值变化。
-
-
-
-
-
-
-
-
-
Search Results
347
records
(took 0.033 seconds)
